Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Alzheimer's drug gets extended test in small patient group

NCT ID NCT05522387

Summary

This study aimed to evaluate the long-term safety and potential effects of an experimental drug called XPro1595 in people with Alzheimer's disease. It was an extension study for 11 participants who had already completed a prior trial with the same drug. The goal was to see if weekly injections for up to 18 months were safe and if they could help slow cognitive decline or improve brain health.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEMENTIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Austin Health

    Ivanhoe, Victoria, 3079, Australia

  • Australian Alzheimer's Research Foundation

    Perth, Western Australia, 6009, Australia

  • KaRa MINDS

    Macquarie Park, New South Wales, 2113, Australia

  • Neuro Trials Victoria Pty Ltd T/A NeuroCentrix

    Carlton, Victoria, 3053, Australia

Conditions

Explore the condition pages connected to this study.